Structure Therapeutics’ (GPCR) Market Outperform Rating Reiterated at Citizens Jmp

Citizens Jmp reiterated their market outperform rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a report issued on Wednesday,Benzinga reports. The brokerage currently has a $110.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research report on Wednesday. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research report on Friday, August 7th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, August 17th. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $38.66 on Wednesday. Structure Therapeutics has a 1 year low of $20.04 and a 1 year high of $94.90. The stock’s 50 day simple moving average is $49.62 and its two-hundred day simple moving average is $48.57. The company has a market cap of $2.69 billion, a price-to-earnings ratio of -38.66 and a beta of -1.45.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, analysts anticipate that Structure Therapeutics will post -1.87 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GPCR. Sterling Capital Management LLC bought a new position in Structure Therapeutics during the 1st quarter valued at about $28,000. State of Wyoming bought a new stake in Structure Therapeutics in the second quarter worth about $28,000. CWM LLC boosted its position in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 125 shares during the period. IFP Advisors Inc purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $46,000. Finally, Assetmark Inc. grew its stake in shares of Structure Therapeutics by 21.4% during the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.